183 related articles for article (PubMed ID: 38400668)
1. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
[TBL] [Abstract][Full Text] [Related]
2. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.
Berlanga P; Ndounga-Diakou LA; Aerts I; Corradini N; Ducassou S; Strullu M; de Carli E; André N; Entz-Werle N; Raimbault S; Roumy M; Renouard M; Gueguen G; Plantaz D; Reguerre Y; Cleirec M; Petit A; Puiseux C; Andry L; Klein S; Bodet D; Kanold J; Briandet C; Halfon-Domenech C; Nelken B; Piguet C; Saumet L; Chastagner P; Benadiba J; Millot F; Pluchart C; Schneider P; Thouvenin S; Gambart M; Serre J; Abbou S; Leruste A; Cayzac H; Gandemer V; Laghouati S; Vassal G
JAMA Netw Open; 2023 Jul; 6(7):e2321568. PubMed ID: 37399010
[TBL] [Abstract][Full Text] [Related]
3. Medical Innovation in a Children's Hospital: 'Diseases desperate grown by desperate appliance are relieved, or not at all'.
Larcher V; Turnham H; Brierley J
Bioethics; 2018 Jan; 32(1):36-42. PubMed ID: 28873231
[TBL] [Abstract][Full Text] [Related]
4. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
6. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
7. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
8. Off-label and compassionate use of targeted anticancer therapies: The experience of an Italian pediatric cancer center.
Cenna R; Basiricò M; Berchialla P; Bertorello N; Cagnazzo C; Ceolin V; De Luna E; Nolis C; Resente F; Fagioli F
Pediatr Blood Cancer; 2023 Mar; 70(3):e30148. PubMed ID: 36583462
[TBL] [Abstract][Full Text] [Related]
9. Success rates for US and Canadian anticancer drug development efforts in pediatric oncology.
Oliviero E; Kourkopoulos G; Kimmelman J
Pediatr Blood Cancer; 2022 Aug; 69(8):e29534. PubMed ID: 35739610
[TBL] [Abstract][Full Text] [Related]
10. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
11. Precision Oncology in Pediatric Cancer Surgery.
Lee WG; Kim ES
Surg Oncol Clin N Am; 2024 Apr; 33(2):409-446. PubMed ID: 38401917
[TBL] [Abstract][Full Text] [Related]
12. Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.
Lim M; Shulman DS; Roberts H; Li A; Clymer J; Bona K; Al-Sayegh H; Ma C; DuBois SG
Cancer Med; 2020 Sep; 9(18):6658-6666. PubMed ID: 32750219
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms.
Sabnis HS; Shulman DS; Mizukawa B; Bouvier N; Zehir A; Fangusaro J; Fabrizio VA; Whitlow C; Winchester M; Agresta L; Turpin B; Wechsler DS; DuBois SG; Glade-Bender J; Castellino SM; Shukla N
J Clin Oncol; 2021 Dec; 39(34):3822-3828. PubMed ID: 34591650
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology.
Shulman DS; Kiwinda LV; Edwards S; Clinton CM; Hunt S; Greenspan L; Lawler KD; Reaman G; Al-Sayegh H; Bona K; O'Neill AF; Shusterman S; Janeway KA; Place AE; Chi SN; Ma C; DuBois SG
Cancer Med; 2021 Apr; 10(7):2310-2318. PubMed ID: 33751835
[TBL] [Abstract][Full Text] [Related]
17. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
18. A review of the experience with pediatric written requests issued for oncology drug products.
Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
[TBL] [Abstract][Full Text] [Related]
19. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
[TBL] [Abstract][Full Text] [Related]
20. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.
Allen CE; Laetsch TW; Mody R; Irwin MS; Lim MS; Adamson PC; Seibel NL; Parsons DW; Cho YJ; Janeway K;
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
